| Peer-Reviewed

Cytoreductive Nephrectomy in Metastatic Kidney Cancer: Experience of the Urology Department at Aristide Le Dantec University Teaching Hospital

Received: 3 August 2021     Accepted: 12 August 2021     Published: 23 August 2021
Views:       Downloads:
Abstract

In the management of metastatic kidney cancer, enlarged nephrectomy is part of a multimodal approach with systemic treatment. The lack of data on its place in the management of metastatic kidney cancer in Africa and particularly in Senegal motivated this study. Aim: to assess the place of cytoreductive nephrectomy in the management of metastatic kidney cancer in our daily practice. Patients and methods: This was a retrospective, descriptive and analytical study from January 2010 to December 2014 on patients aged 18 years and over operated for metastatic kidney cancer. The variables studied were prognostic: Performance Status, tumor stage, sites and number of metastatic sites, prognosis group according to Heng's model, histological type and Furhman grade of the nephrectomy specimen, follow-up postoperative course and overall survival. Results: A total of 12 patients were included. The mean size of the largest axis of the tumors was 14.06±5.3 cm with extremes of 8.2 and 23.8 cm and the tumor was graded T3 in 6 cases. The majority of patients had a single metastatic site and the lung was the most common metastatic site in 9 cases. In half of the cases the ECOG-PS score was 1. In 6 cases the patients were classified in the Heng intermediate prognosis group. Lymph node dissection was associated with nephrectomy in 4 cases. Renal adenocarcinoma was the most common histologic type in 8 cases and Furhman's grade was only specified in 6 cases. The mean duration of follow-up was 10.1±13.4 months (range 1 and 39 months), overall survival at 2 years was poor and only 2 patients were alive 3 years and 4 years after their nephrectomy. Conclusion: metastatic kidney cancer is uncommon in our context, most of our patients consult with advanced stage tumors. Systemic treatment remains difficult for our populations to access. Nephrectomy remains the main weapon at our disposal.

Published in International Journal of Clinical Urology (Volume 5, Issue 2)
DOI 10.11648/j.ijcu.20210502.14
Page(s) 74-79
Creative Commons

This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.

Copyright

Copyright © The Author(s), 2021. Published by Science Publishing Group

Keywords

Cytoreductive Nephrectomy, Metastatic Kidney Cancer, Overall Survival

References
[1] Chow WH, Devesa SS. Contemporary epidemiology of renal cell cancer. Cancer J. 2008; 14 (5): 288-301.
[2] Fall B, Diao B, Sow Y, Sarr A, Thiam A, Fall PA, Ndoye AK, Sylla C, Ba M, Mendes V, Diagne BA. Le cancer du rein de l’adulte au Sénégal: aspects épidémiologiques et cliniques actuels et évolution du profil sur les deux dernières décennies. Prog Urol. 2011; 21 (8): 521-6.
[3] Motzer RJ, Bacik J, Schwartz LH, Reuter V, Russo P, Marion S, Mazumdar M. Prognostic factor for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol. 2004; 22 (3): 454-63.
[4] Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med. 2005; 353 (23): 2477-90.
[5] Flanigan RC, Salmon SE, Blumenstein BA, Bearman SI, Roy V, McGrath PC et al. Nephrectomy followed by Interferon alpha-2b compared with Interferon alpha-2b alone for metastatic renal cell cancer. N Engl J Med. 2001; 345 (23): 1655-9.
[6] Mickisch GHJ, Garin A, van Poppel H, de prijck L, Sylvester R. European Organisation for Research and Treatment of Cancer (EORTC) Genitourinary Group. Radical nephrectomy plus Interferon-alpha-based immunotherapy compared with Interferon alpha alone in metastatic renal-cell carcinoma: a randomised trial. Lancet. 2001; 358 (9286): 966-70. doi: 10.1016/s0140-6736(01)06103-7.
[7] Gupta K, Miller JD, Li JZ, Russell MW, Charbonneau C. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat Rev. 2008; 34 (3): 193-205. doi: 10.1016/j.crtv.2007.12.001.
[8] Tengue K, Kpatcha TM, Sonhaye L, Amavi AK, Leloua E, Botcho G et al. Le cancer du rein de l’adulte au Togo: fréquence, diagnostic, traitement et évolution. Uro Andro. 2015; 1 (4): 177-182.
[9] Rebillard X, Grosclaude P, Leone N, Velten M, Coureau G, Villers A et al. Projection de l’incidence et de la mortalité par cancer urologique en France en 2021. Prog Urol. 2013; 23 Suppl 2: S57-S65. doi: 10.1016/S1166-7087(13)70047-2.
[10] Chow WH, Dong LM, Devesa SS. Epidemiology and risk factors for kidney cancer. Nat Rev Urol. 2010; 7 (5): 245-57. doi: 10.1038/nrurol.2010.46.
[11] Karim-Kos HE, de Vries E, Soerjomataram I, Lemmens V, Siesling S, W. Coebergh JW. Recent trends of cancer in Europe: a combined approach of incidence, survival and mortality for 17 cancers sites since the 1990s. Eur J Cancer. 2008; 44 (10): 1345-89. doi: 10.1016/j.ejca.2007.12.015.
[12] Réseau Canadien de recherche en cancer du rein. Prise en charge du cancer du rein de stade avancé: mise à jour 2013 des lignes directrices consensuelles du forum canadien sur le cancer du rein. Toronto: RCRCR; 2013.
[13] Eheman C, Henley J, Ballard-Barbash R, Jacobs EJ, Schymura MJ, Noone AM et al. Annual report to the nation on the status of cancer, 1975-2008, featuring cancers associated with excess weight and lack of sufficient activity. Cancer. 2012; 118 (9): 2338-66. doi: 10.1002/cncr.27514.
[14] Culp SH, Karam JA, Wood CG. Population-based analysis of factors associated with survival in patients undergoing cytoreductive nephrectomy in the targeted therapy era. Urol Oncol. 2014; 32 (5): 561-8. doi: 10.1016/j.urolonc.2013.12.003.
[15] Eggener SE, Yossepowitch O, Pettus JA, Snyder ME, Motzer RJ, Russo P. Renal cell carcinoma recurrence after nephrectomy for localized disease: predicting survival form time of recurrence. J Clin Oncol. 2006; 24 (19): 3101-6. doi: 10.1200/JCO.2005.04.8280.
[16] Antonelli A, Cozzoli A, Zani D, Zanotelli D, Nicolai M, Cunico SC, Simeone C. The follow-up management of non-metastatic renal cell carcinoma: definition of a surveillance protocol. BJU Int. 2007; 99 (2): 296-300. doi: 10.1111/j.1464.-410x.2006.06616.x.
[17] Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O et al. Sunitinib versus Interferon alpha in metastatic renal-cell carcinoma. N Engl J Med. 2007; 356 (2): 115-24. doi: 10.1056/NEJMoa065044.
[18] Négrier S, Escudier B, Gomez F, Douillard JY, Ravaud A, Chevreau C et al. Prognostics factors of survival and rapid progression in 782 patients with metastatic renal cell carcinomas treated by cytokines: a report from the Group Français d’Immunothérapie. Ann Oncol. 2002; 13 (9): 1460-8. doi: 10.1093/annonc/mdf257.
[19] Han KR, Pantuck AJ, Bui MH, Shvarts O, Freitas DG, Zisman A et al. Number of metastatic sites rather than location dictates overall survival of patients with node-negative metastatic renal cell carcinoma. Urology. 2003; 61 (2): 314-9. doi: 10.1016/s0090-4295(02)02163-5.
[20] Patard JJ, Baumert H, Bensalah K, Bernhard JC, Bigot P, Escudier B et al. CCAFU recommendations 2013: renal cancer. Prog Urol. 2013; 23 Suppl 2: S177-204. French. doi: 10.1016/S1166-7087(13)70055-1.
[21] Heng D, Xie W, Regan MM, Harshman LC, Bjarnason GA, Vaishampayan UN et al. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol. 2013; 14 (2): 141-8. doi: 10.1016/S1470-2045(12)70559-4.
[22] Shuch B, Riggs SB, LaRochelle JC, Kabbinavar FF, Avakian R, Pantuck AJ et al. Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm. BJU Int. 2008; 102 (6): 692-6. doi: 10.1111/j.1464.-410X.2008.07660.x.
[23] Leibovich BC, Han KR, Bui MH, Pantuck AJ, Dorey FJ, Figling RA et al. Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer. 2003; 98 (12): 2566-75. doi: 10.1002/cncr.11851.
[24] Rabets JC, Kaouk J, Fergany A, Finelli A, Gill IS, Novick AC. Laparoscopic versus open cytoreductive nephrectomy for metastatic renal cell carcinoma. Urology. 2004; 64 (5): 930-4. doi: 10.1016/j.urology.2004.06.052.
[25] Finelli A, Kaouk JH, Fergany AF, Abreu SC, Novick AC, Gill IS. Laparoscopic cytoreductive nephrectomy for metastatic renal cell carcinoma. BJU Int. 2004; 94 (3): 291-4. doi: 10.1111/j.1464-410X.2004.04925.x.
[26] Matin SF, Madsen LT, Wood CG. Laparoscopic cytoreductive nephrectomy: the M. D. Anderson Cancer Center experience. Urology. 2006; 68 (3): 528-32. doi: 10.1016/j.urology.2006.03.076.
[27] Eisenberg MS, Meng MV, Master VA, Stoller ML, Rini BI, Carroll PR, Kane CJ. Laparoscopic versus open cytoreductive nephrectomy in advanced renal cell-carcinoma. J Endourol. 2006; 20 (7): 504-8. doi: 10.1089/end.2006.20.504.
[28] Ganeshappa A, Sundaram C, Lerner MA, Gardner TA. Role of the laparoscopic approach to cytoreductive nephrectomy in metastatic renal-cell carcinoma: does size matter? J Endourol. 2010; 24 (8): 1289-92. doi: 10.1089/end.2009.0401.
[29] Blick C, Bott S, Muneer A, Barber NJ, Hindley R, Eden C, Sullivan M. Laparoscopic cytoreductive nephrectomy: a three-center retrospective analysis. J Endourol. 2010; 24 (9): 1451-5. doi: 10.1089/end.2009.0458.
[30] Bex A, Ljungberg B, van Poppel H, Powles T; European Association of Urology. The Role of Cytoreductive Nephrectomy: European Association of Urology recommendations in. Eur Urol. 2016; 70 (6): 901-905. doi: 10.1016/j.eururo.2016.07.005.
[31] Patard JJ, Baumert H, Corréas JM, Escudier B, Lang H, Long JA et al. Oncology Committee of the French Association of Urology (CCAFU). Recommendations Onco-Urology 2010: Kidney cancer. Prog Urol. 2010; 20 Suppl 4: S319-39. French. doi: 10.1016/S1166-7087(10)70048-8.
[32] Méjean A, Ravaud A, Thezenas S, Colas S, Beauval JB, Bensalah K et al. Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma. N Engl J Med. 2018 Aug 2; 379 (5): 417-427. doi: 10.1056/NEMJoa1803675.
[33] Flanigan RC, Mickisch G, Sylvester R, Tangen C, Van Poppel H, Crawford ED. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol. 2004; 171 (3): 1071-6. doi: 10.1097/01.ju.0000110610.61545.ae.
Cite This Article
  • APA Style

    Boris Amougou, Yaya Sow, Arlette Dongmo, David Douglas Banga Nkomo, Jean Paul Engbang, et al. (2021). Cytoreductive Nephrectomy in Metastatic Kidney Cancer: Experience of the Urology Department at Aristide Le Dantec University Teaching Hospital. International Journal of Clinical Urology, 5(2), 74-79. https://doi.org/10.11648/j.ijcu.20210502.14

    Copy | Download

    ACS Style

    Boris Amougou; Yaya Sow; Arlette Dongmo; David Douglas Banga Nkomo; Jean Paul Engbang, et al. Cytoreductive Nephrectomy in Metastatic Kidney Cancer: Experience of the Urology Department at Aristide Le Dantec University Teaching Hospital. Int. J. Clin. Urol. 2021, 5(2), 74-79. doi: 10.11648/j.ijcu.20210502.14

    Copy | Download

    AMA Style

    Boris Amougou, Yaya Sow, Arlette Dongmo, David Douglas Banga Nkomo, Jean Paul Engbang, et al. Cytoreductive Nephrectomy in Metastatic Kidney Cancer: Experience of the Urology Department at Aristide Le Dantec University Teaching Hospital. Int J Clin Urol. 2021;5(2):74-79. doi: 10.11648/j.ijcu.20210502.14

    Copy | Download

  • @article{10.11648/j.ijcu.20210502.14,
      author = {Boris Amougou and Yaya Sow and Arlette Dongmo and David Douglas Banga Nkomo and Jean Paul Engbang and Theodore Sala Beyeme and Joseph Fondop and Demba Cisse and Faustin Atemkeng and Boubacar Fall and Babacar Diao and Abdoulaye Bobo Diallo and Alain Khassim Ndoye and Fru Angwafor III and Mamadou Ba},
      title = {Cytoreductive Nephrectomy in Metastatic Kidney Cancer: Experience of the Urology Department at Aristide Le Dantec University Teaching Hospital},
      journal = {International Journal of Clinical Urology},
      volume = {5},
      number = {2},
      pages = {74-79},
      doi = {10.11648/j.ijcu.20210502.14},
      url = {https://doi.org/10.11648/j.ijcu.20210502.14},
      eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijcu.20210502.14},
      abstract = {In the management of metastatic kidney cancer, enlarged nephrectomy is part of a multimodal approach with systemic treatment. The lack of data on its place in the management of metastatic kidney cancer in Africa and particularly in Senegal motivated this study. Aim: to assess the place of cytoreductive nephrectomy in the management of metastatic kidney cancer in our daily practice. Patients and methods: This was a retrospective, descriptive and analytical study from January 2010 to December 2014 on patients aged 18 years and over operated for metastatic kidney cancer. The variables studied were prognostic: Performance Status, tumor stage, sites and number of metastatic sites, prognosis group according to Heng's model, histological type and Furhman grade of the nephrectomy specimen, follow-up postoperative course and overall survival. Results: A total of 12 patients were included. The mean size of the largest axis of the tumors was 14.06±5.3 cm with extremes of 8.2 and 23.8 cm and the tumor was graded T3 in 6 cases. The majority of patients had a single metastatic site and the lung was the most common metastatic site in 9 cases. In half of the cases the ECOG-PS score was 1. In 6 cases the patients were classified in the Heng intermediate prognosis group. Lymph node dissection was associated with nephrectomy in 4 cases. Renal adenocarcinoma was the most common histologic type in 8 cases and Furhman's grade was only specified in 6 cases. The mean duration of follow-up was 10.1±13.4 months (range 1 and 39 months), overall survival at 2 years was poor and only 2 patients were alive 3 years and 4 years after their nephrectomy. Conclusion: metastatic kidney cancer is uncommon in our context, most of our patients consult with advanced stage tumors. Systemic treatment remains difficult for our populations to access. Nephrectomy remains the main weapon at our disposal.},
     year = {2021}
    }
    

    Copy | Download

  • TY  - JOUR
    T1  - Cytoreductive Nephrectomy in Metastatic Kidney Cancer: Experience of the Urology Department at Aristide Le Dantec University Teaching Hospital
    AU  - Boris Amougou
    AU  - Yaya Sow
    AU  - Arlette Dongmo
    AU  - David Douglas Banga Nkomo
    AU  - Jean Paul Engbang
    AU  - Theodore Sala Beyeme
    AU  - Joseph Fondop
    AU  - Demba Cisse
    AU  - Faustin Atemkeng
    AU  - Boubacar Fall
    AU  - Babacar Diao
    AU  - Abdoulaye Bobo Diallo
    AU  - Alain Khassim Ndoye
    AU  - Fru Angwafor III
    AU  - Mamadou Ba
    Y1  - 2021/08/23
    PY  - 2021
    N1  - https://doi.org/10.11648/j.ijcu.20210502.14
    DO  - 10.11648/j.ijcu.20210502.14
    T2  - International Journal of Clinical Urology
    JF  - International Journal of Clinical Urology
    JO  - International Journal of Clinical Urology
    SP  - 74
    EP  - 79
    PB  - Science Publishing Group
    SN  - 2640-1355
    UR  - https://doi.org/10.11648/j.ijcu.20210502.14
    AB  - In the management of metastatic kidney cancer, enlarged nephrectomy is part of a multimodal approach with systemic treatment. The lack of data on its place in the management of metastatic kidney cancer in Africa and particularly in Senegal motivated this study. Aim: to assess the place of cytoreductive nephrectomy in the management of metastatic kidney cancer in our daily practice. Patients and methods: This was a retrospective, descriptive and analytical study from January 2010 to December 2014 on patients aged 18 years and over operated for metastatic kidney cancer. The variables studied were prognostic: Performance Status, tumor stage, sites and number of metastatic sites, prognosis group according to Heng's model, histological type and Furhman grade of the nephrectomy specimen, follow-up postoperative course and overall survival. Results: A total of 12 patients were included. The mean size of the largest axis of the tumors was 14.06±5.3 cm with extremes of 8.2 and 23.8 cm and the tumor was graded T3 in 6 cases. The majority of patients had a single metastatic site and the lung was the most common metastatic site in 9 cases. In half of the cases the ECOG-PS score was 1. In 6 cases the patients were classified in the Heng intermediate prognosis group. Lymph node dissection was associated with nephrectomy in 4 cases. Renal adenocarcinoma was the most common histologic type in 8 cases and Furhman's grade was only specified in 6 cases. The mean duration of follow-up was 10.1±13.4 months (range 1 and 39 months), overall survival at 2 years was poor and only 2 patients were alive 3 years and 4 years after their nephrectomy. Conclusion: metastatic kidney cancer is uncommon in our context, most of our patients consult with advanced stage tumors. Systemic treatment remains difficult for our populations to access. Nephrectomy remains the main weapon at our disposal.
    VL  - 5
    IS  - 2
    ER  - 

    Copy | Download

Author Information
  • Department of Surgery and Surgical Specialties, University of Dschang, Dschang, Cameroon

  • Department of Surgery and Surgical Specialties, Gaston Berger University, Saint Louis, Senegal

  • Department of Surgery and Surgical Specialties, University of Dschang, Dschang, Cameroon

  • Department of Surgery and Surgical Specialties, University of Dschang, Dschang, Cameroon

  • Faculty of Medecine and Pharmaceutical Sciences, University of Douala, Douala, Cameroon

  • Faculty of Medecine and Pharmaceutical Sciences, University of Douala, Douala, Cameroon

  • Department of Surgery and Surgical Specialties, University of Dschang, Dschang, Cameroon

  • Faculty of Medecine and Pharmacy, Gamal Abdel Nasser University, Conakry, Guinea

  • Department of Surgery and Surgical Specialties, University of Dschang, Dschang, Cameroon

  • Faculty of Health Sciences, Ziguinchor Assan Seck University, Ziguinchor, Senegal

  • Department of Surgery, Cheikh Anta Diop University, Dakar, Senegal

  • Faculty of Medecine and Pharmacy, Gamal Abdel Nasser University, Conakry, Guinea

  • Department of Surgery, Cheikh Anta Diop University, Dakar, Senegal

  • Department of Surgery, University of Yaoundé 1, Yaounde, Cameroon

  • Department of Surgery, Cheikh Anta Diop University, Dakar, Senegal

  • Sections